Blog
RSS FeedPosted by Michael Wonder on 12 Dec 2019
Alberta will force patients to switch from biologics to cheaper biosimilar medications
12 December 2019 - Alberta will force 26,000 patients on government-sponsored drug plans to switch from expensive drugs that are known ...
Posted by Michael Wonder on 05 Dec 2019
Is it time to look beyond price with biosimilars?
5 December 2019 - While there is no question that falling prices that come with competition are cause for optimism in ...
Posted by Michael Wonder on 02 Dec 2019
Biosimilar trastuzumab on the PBS - information for health professionals and patients
2 December 2019 - A new biosimilar brand of trastuzumab (Kanjinti) has listed on the PBS on 1 December 2019. ...
Posted by Michael Wonder on 18 Nov 2019
Biosimilars make progress in the Canadian market, but stakeholders see more work ahead
18 November 2019 - While much attention over the past few weeks has been on the US biosimilars market, with its ...
Posted by Michael Wonder on 14 Nov 2019
Biosimilar rituximab and insulin glargine on the PBS and other PBS Listing changes - information for health professionals and patients
14 November 2019 - Biosimilar brands of rituximab (Riximyo) and insulin glargine (Semglee) have listed on the PBS on 1 October ...
Posted by Michael Wonder on 10 Oct 2019
Biosimilars in the UK: where are we now and where does the NHS want to go?
9 October 2019 - The UK health service has well over a decade’s experience of dealing with biosimilars, but the ...
Posted by Michael Wonder on 27 Sep 2019
With Brexit looming, what does the future hold for UK biosimilars?
26 September 2019 - If and when the United Kingdom leaves the European Union, the Medicines and Healthcare Products Regulatory Agency ...
Posted by Michael Wonder on 10 Sep 2019
Erosion of physician and patient treatment choice continues - Alliance for Safe Biologic Medicines raises concerns for patients as British Columbia expands biologics forced switching policy
10 September 2019 - On 5 September, the Government of British Columbia announced that it would be forcibly switching 1,700 patients ...
Posted by Michael Wonder on 02 Aug 2019
Mylan and Biocon launch first trastuzumab biosimilar Ogivri in Australia
1 August 2019 - Biocon and Mylan today announced the launch in Australia of Ogivri (trastuzumab), a biosimilar to Herceptin ...
Posted by Michael Wonder on 20 Jul 2019
Biosimilar drugs a boon to be applauded as they provide equivalent treatment at – sometimes – half the price
19 July 2019 - The fastest-growing segment of our health-care system is prescription drugs – now constituting the second-highest category ...
Posted by Michael Wonder on 17 Jul 2019
Majority of patients not asked for consent before being switched to a biosimilar, survey finds
17 July 2019 - The preliminary survey results showed that 52% of patients received a letter from hospital about switching to ...
Posted by Michael Wonder on 24 Jun 2019
Forcing patients to switch to biosimilars puts them in uncharted waters
23 June 2019 - On May 27, the B.C. government announced a policy that will forcibly switch thousands of patients, ...
Posted by Michael Wonder on 18 Jun 2019
Advisory Council supports biosimilars in call for universal public drug coverage in Canada
17 June 2019 - A Canadian advisory council is recommending the use of biosimilars in a final report that lays ...
Posted by Michael Wonder on 06 Jun 2019
Patients, physicians raise concerns with BC biosimilar non-medical switching policy
6 June 2019 - On 27 May, the Government of British Columbia announced a policy that will forcibly switch thousands ...
Posted by Michael Wonder on 06 Jun 2019
Decision to widen access to etanercept and award sole supply
6 June 2019 - PHARMAC has made a decision to make changes to the funding of etanercept, a biologic medicine ...